Tumor formation in preneoplastic mammary nodule lines in mice treated with nafoxidine, testosterone, and 2-bromo-alpha-ergocryptine.
The tumor potentials of five preneoplastic mammary nodule lines were examined in BALB/cCrgl mice treated with either nafoxidine, an estrogen antagonist; 2-bromo-alpha-ergocryptine, a prolactin suppressant; or testosterone. The inhibitory effect of any of the three agents was dependent on the individual nodule line and was not correlated with the effects of ovariectomy. Nafoxidine inhibited tumor formation only in nodule line D2; testosterone inhibited tumor formation in lines C3 and C4; and 2-bromo-alpha-ergocryptine failed to inhibit tumor formation in any of the nodule lines. These results provided information on the range of responses of mouse preneoplastic mammary tissues to a variety of antihormone treatments and suggested that responses to ovariectomy need not be correlated with responses to specific antihormone treatments.
D000818:Animals; D001971:Bromocriptine / Q000627:therapeutic use*; D004873:Ergolines / Q000627:therapeutic use*; D005260:Female; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy* / Q000378:metabolism; D051379:Mice; D008807:Mice, Inbred BALB C; D009256:Nafoxidine / Q000627:therapeutic use*; D009368:Neoplasm Transplantation; D010053:Ovary / Q000502:physiology; D011230:Precancerous Conditions / Q000188:drug therapy* / Q000378:metabolism; D011759:Pyrrolidines / Q000627:therapeutic use*; D011944:Receptors, Androgen / Q000187:drug effects; D011960:Receptors, Estrogen / Q000187:drug effects; D013739:Testosterone / Q000627:therapeutic use*; D014185:Transplantation, Isogeneic
D004873:Ergolines; D011759:Pyrrolidines; D011944:Receptors, Androgen; D011960:Receptors, Estrogen; D001971:Bromocriptine; D013739:Testosterone; D009256:Nafoxidine